StockStory Cites Weak Sales and Profitability at Three Healthcare Firms
The publisher points to weak sales trends, falling earnings per share and shrinking cash flow measures across the three companies.
Key takeaways
- StockStory says Teleflex’s earnings per share fell 6.5% annually over five years.
- Enovis sales were flat over five years, while earnings per share fell 9.5% annually.
- Ocular Therapeutix sales fell 7.7% annually over two years, according to StockStory.
StockStory named Teleflex, Enovis and Ocular Therapeutix as healthcare stocks it views as risky, citing weak sales trends and declining profitability.
The publisher said Teleflex’s earnings per share fell 6.5% annually over five years, while its constant-currency revenue growth disappointed over the past two years. Enovis had flat sales over five years, and its earnings per share fell 9.5% annually during that period.
For Ocular Therapeutix, StockStory cited sales declines of 7.7% annually over two years. It also said earnings per share fell 7.5% annually over five years and the company’s free cash flow margin shrank by 371.3 percentage points over that span.
This article was produced with the help of AI technology. Source: Yahoo Finance
